Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-EVEREST: REGN7508 versus apixaban for prevention of stroke and systemic embolism in atrial fibrillation
2025-521617-97-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Cenvacibart arm with Apixaban arm (2 arms). Primary endpoints: Stroke or systemic embolism and Major or clinically relevant non-major bleeding. Planned start Sep 2026; status: authorised.
02
Drugs
cenvacibartapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-521617-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521617-97-00.